Department of Medicine

September 29, 2022

Study shows CMS reimbursement not associated with wider EPD use

Vanderbilt research shows that higher reimbursement from the Centers for Medicare & Medicaid Services was not associated with wider use of an embolic protection device during transcatheter aortic valve replacement procedures.

By Matt Batcheldor
September 28, 2022

October Medicine Grand Rounds announced

By VUMC News and Communications
September 27, 2022

Diagnostic biomarker for bone disorder

A urine chemical performs better as a diagnostic biomarker for the soft bone disease hypophosphatasia than other laboratory measures, Vanderbilt researchers have demonstrated.

By Leigh MacMillan
September 22, 2022

Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award

Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).  

By Bill Snyder
September 22, 2022

Reduced exercise capacity in ICU survivors

ICU survivors who have impaired exercise capacity months after discharge may have damaged muscle mitochondria — the energy powerhouses of the cell, Vanderbilt researchers propose.

By Kelsey Pinckard
The study could suggest ways to promote the transport of phospholipids and cholesterol out of macrophages, immune system cells that play key roles in all stages of atherosclerosis development.
September 15, 2022

Study suggests new mechanism for lipid transporter

A new model suggests that a protein involved in the generation of high-density lipoprotein (HDL) works differently than previously thought.

By Leigh MacMillan
September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.
By Tom Wilemon
September 13, 2022

VUMC leads effort to map heart disease-causing genetic variations

Researchers from Vanderbilt University Medical Center, Stanford Medicine, the University of Toronto and Brigham and Women’s Hospital in Boston have joined forces to “map” the specific variations in more than 25 key cardiac disease genes that negatively affect heart function.
By Bill Snyder
September 8, 2022

PheWAS reveals post-COVID-19 diagnoses

Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.
By Bill Snyder
August 30, 2022

A new mechanism for lupus

Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.
By Leigh MacMillan
August 29, 2022

Blood cancer progression

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.
By Leigh MacMillan
August 25, 2022

New high-tech biobank safeguards critical specimens

By Bill Snyder
August 25, 2022

Rheumatoid arthritis and heart disease: a common path

An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.
By Bill Snyder
1 … 31 32 33 34 35 … 114